<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893398</url>
  </required_header>
  <id_info>
    <org_study_id>FdG_AD_01</org_study_id>
    <nct_id>NCT01893398</nct_id>
  </id_info>
  <brief_title>Multistimulation Group Therapy for Alzheimer's Disease</brief_title>
  <official_title>Multistimulation Group Therapy in Mild to Moderate Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Don Carlo Gnocchi Onlus</source>
  <brief_summary>
    <textblock>
      Our previous findings support the notion that group activity program, based on cognitive
      stimulation, recreational-occupational activities and physical-psychomotor exercises, can
      lead to an improvement in behavioral aspects for people with Alzheimer's Disease (AD).

      The purpose of this study is to clarify the efficacy of a rehabilitation program in
      outpatients affected by AD in mild to moderate stages.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in behavioral level</measure>
    <time_frame>Baseline, 10ws, 22ws</time_frame>
    <description>Neuropsychiatric Inventory scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in cognitive level</measure>
    <time_frame>Baseline, 10ws, 22 ws</time_frame>
    <description>ADAS cog scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in quality of life</measure>
    <time_frame>baseline, 10ws,22 ws</time_frame>
    <description>SF36 questionaire</description>
  </primary_outcome>
  <other_outcome>
    <measure>Functional MRI</measure>
    <time_frame>baseline, 10 ws</time_frame>
    <description>Change from baseline in brain functioning. We used fMRI with cognitive task to detect possible changes (10 ws versus baseline) in brain activation patterns in PWA as a surrogate biomarker of efficacy.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>rehabilitation (MST) program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Multidimensional Stimulation group therapy (MST) involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual care program</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual care PWA program</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Multidimensional stimulation group therapy</intervention_name>
    <description>The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.</description>
    <arm_group_label>rehabilitation (MST) program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of possible/probable AD

          -  mild to moderate stage of AD (MMSE score of 15 - 24)and CDR score of 1-2

          -  range years in age (65-85) and in school attendance (5-17)

          -  right handed

        Exclusion Criteria:

          -  severe aphasia (Token test score &lt; 20)

          -  severe auditory and/or visual loss

          -  overt severe behavioral disturbances (delusions, hallucinations, agitation)

          -  recent (three month before the MST) introduction or dose modification of the following
             pharmacological treatments: cholinesterase inhibitor, memantine, antidepressant or
             antipsychotic drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>IRCCS, S Maria Nascente, FOndazione don Gnocchi</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>http://www.dongnocchi.it/</url>
  </link>
  <reference>
    <citation>Farina E, Mantovani F, Fioravanti R, Pignatti R, Chiavari L, Imbornone E, Olivotto F, Alberoni M, Mariani C, Nemni R. Evaluating two group programmes of cognitive training in mild-to-moderate AD: is there any difference between a 'global' stimulation and a 'cognitive-specific' one? Aging Ment Health. 2006 May;10(3):211-8.</citation>
    <PMID>16777648</PMID>
  </reference>
  <reference>
    <citation>Farina E, Fioravanti R, Chiavari L, Imbornone E, Alberoni M, Pomati S, Pinardi G, Pignatti R, Mariani C. Comparing two programs of cognitive training in Alzheimer's disease: a pilot study. Acta Neurol Scand. 2002 May;105(5):365-71.</citation>
    <PMID>11982487</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>July 2, 2013</last_update_submitted>
  <last_update_submitted_qc>July 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

